易明医药(002826) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥177,538,389.36, an increase of 10.37% compared to the same period last year[4] - Net profit attributable to shareholders was ¥44,206,127.26, reflecting a significant increase of 1,934.12% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥14,925,118.20, up by 275.79% compared to the previous year[4] - Basic earnings per share for the period was ¥0.24, representing a 2,300.00% increase year-on-year[5] - Total operating revenue for the current period was ¥488,983,972.66, a decrease of 4.3% from ¥512,843,177.87 in the previous period[29] - Operating profit increased to ¥89,326,733.14, up 74.4% from ¥51,223,379.81 in the previous period[30] - Net profit for the current period was ¥81,763,271.44, a significant increase of 92.0% compared to ¥42,620,637.91 in the previous period[30] - Basic and diluted earnings per share both rose to ¥0.44, doubling from ¥0.22 in the previous period[31] Assets and Equity - Total assets at the end of the reporting period amounted to ¥1,058,773,560.13, a growth of 14.28% from the end of the previous year[5] - Total assets increased to ¥1,058,773,560.13, up from ¥926,469,234.87, reflecting a growth of 14.2%[27] - Total equity attributable to shareholders increased to ¥802,146,877.46, marking an 8.54% rise from the previous year[5] - Total equity attributable to shareholders increased to ¥802,146,877.46 from ¥739,003,677.36, a growth of 8.5%[27] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥149,597,994.83, up by 31.41% compared to the same period last year[4] - Operating cash flow net increased by 31.41% year-on-year, driven by higher sales and government subsidies[11] - Cash inflow from operating activities totaled $600,000,709.14, a decrease of 1.6% from $611,482,717.11 in the previous period[34] - Net cash flow from operating activities increased to $149,597,994.83, up 31.5% from $113,837,202.53 in the previous period[34] - Total cash outflow from operating activities was $450,402,714.31, down from $497,645,514.58 in the previous period[34] Operating Costs and Expenses - The company's operating costs decreased by 48.35% to ¥87,288,420.68 compared to the same period last year[9] - Total operating costs decreased to ¥435,575,357.61 from ¥488,755,312.52, representing a reduction of 10.9%[29] - The company reported a significant reduction in research and development expenses to ¥9,875,884.83 from ¥12,082,095.39, a decrease of 18.3%[29] Investments and Financial Management - The company received government subsidies totaling ¥19,577,657.21 during the reporting period, contributing positively to its financial performance[6] - Investment income rose by 100.36% year-on-year, mainly attributed to increased returns from financial product investments[10] - The company reported a loss of 161.03 million yuan from its financial investments during the reporting period[22] - The company has engaged in various fixed income investments with different banks, including China Bank and Agricultural Bank, with amounts ranging from 1,000,000 to 10,000,000 yuan[22] - The expected annualized return rates for various investments range from 1.3% to 2.9%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 19,437[13] - The largest shareholder, Beijing Fuhai Enterprise Management Partnership, holds 23.00% of the shares[13] - Beijing Fuhai Enterprise Management Partnership holds 43,855,883 shares, accounting for 23.00% of the total shares, making it the largest shareholder[15] - The company has a total of 3,403,800 shares held in the repurchase special securities account, representing 1.79% of the total share capital[15] Changes in Management and Control - The third board of directors has been replaced, with the fourth board consisting of 3 non-independent directors and 3 independent directors[17] - The company completed the share transfer agreement on August 19, 2025, changing the controlling shareholder from Gao Fan to Beijing Fuhai[15] - The company has not reported any overdue amounts or impairment losses related to its entrusted financial management[19] - The company’s major shareholders have not participated in margin trading or securities lending activities[15] - The company has not disclosed any changes in the number of preferred shareholders or their holdings[15] - The company has not reported any significant changes in the control rights or related party transactions[15] - The company has not indicated any involvement in financing or securities lending activities among the top shareholders[15]